Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 76 Neoplasms 16 Prostatic Neoplasms, Castration-Resistant 14 Neoplasm Metastasis 9 Breast Neoplasms 9 Metastatic Castration Resistant Prostate Cancer 8 Prostate Cancer Metastatic 5 Metastatic Castration-Resistant Prostate Cancer 5 Colorectal Neoplasms 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Carcinoma, Non-Small-Cell Lung 4 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Metastatic Castration-resistant Prostate Cancer 3 Melanoma 3 Bulbo-Spinal Atrophy, X-Linked 3 mCRPC 2 Recurrence 2 Pancreatic Neoplasms 2 Non-metastatic Castration-resistant Prostate Cancer 2 Metastatic Hormone-sensitive Prostate Cancer 2 Metastatic Hormone Sensitive Prostate Cancer 2 Metastatic Castrate-Resistant Prostate Cancer 2 Carcinoma, Renal Cell 2 Carcinoma, Hepatocellular 2 Bites and Stings 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Solid Tumours 1 Seizures 1

Interventions

enzalutamide 1 darolutamide 1 apalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Non-metastatic Prostate Cancer × enzalutamide × Clear all

NCT06204302 2024-04-09

ARENA

Bayer

Non-metastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡